Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pakneshan, P.
Right arrow Articles by Rabbani, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pakneshan, P.
Right arrow Articles by Rabbani, S. A.
Clinical Cancer Research Vol. 10, 3035-3041, May 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma

Pouya Pakneshan1, Bernard Têtu2 and Shafaat A. Rabbani1

1 Departments of Medicine and Oncology, McGill University Health Center, Montreal, Canada, and 2 Department of Pathology, Université Laval, Quebec, Canada

Purpose: Urokinase (uPA) is expressed in a number of highly invasive malignancies including breast cancer. Because production of uPA is associated with breast cancer progression and can serve as a useful prognostic marker, the purpose of this study was to examine the role of uPA promoter methylation as an indicator of uPA production in breast cancer patients.

Experimental Design: We examined the methylation status of the uPA promoter and the levels of uPA expression in normal human breast epithelial cells and several human breast cancer cells by bisulfite sequencing analysis and reverse transcription-PCR. We also analyzed the methylation status of the uPA promoter in surgical biopsy samples from patients with breast cancer of different grades, as determined by the Elston-Ellis histological grading system.

Results: Expression of uPA mRNA was only detected in the highly invasive estrogen receptor-negative breast cancer cell lines, where the promoter was completely demethylated. In normal and low invasive breast cancer cells, the uPA promoter was methylated, resulting in lack of uPA mRNA expression. Analysis of biopsy samples showed that demethylation of the uPA promoter is associated with malignant transformation. Reverse transcription-PCR analysis revealed that this demethylation of the uPA promoter is directly associated with induction of uPA mRNA expression, which is well known to be associated with poor prognosis in breast cancer patients.

Conclusions: This study indicated that uPA expression in breast cancer patients is under epigenetic control via methylation of its promoter. Determination of uPA promoter methylation can therefore serve as an early reliable indicator of uPA production in breast cancer patients.




This article has been cited by other articles:


Home page
J. Histochem. Cytochem.Home page
D. Dietrich, R. Lesche, R. Tetzner, M. Krispin, J. Dietrich, W. Haedicke, M. Schuster, and G. Kristiansen
Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues
J. Histochem. Cytochem., May 1, 2009; 57(5): 477 - 489.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
O. Hartmann, F. Spyratos, N. Harbeck, D. Dietrich, A. Fassbender, M. Schmitt, S. Eppenberger-Castori, V. Vuaroqueaux, F. Lerebours, K. Welzel, et al.
DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Clin. Cancer Res., January 1, 2009; 15(1): 315 - 323.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani
A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1580 - 1588.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. K. Pulukuri, N. Estes, J. Patel, and J. S. Rao
Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer
Cancer Res., February 1, 2007; 67(3): 930 - 939.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Paredes, A. Albergaria, J. T. Oliveira, C. Jeronimo, F. Milanezi, and F. C. Schmitt
P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation
Clin. Cancer Res., August 15, 2005; 11(16): 5869 - 5877.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P. Pakneshan, M. Szyf, and S. A. Rabbani
Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells
Carcinogenesis, March 1, 2005; 26(3): 557 - 564.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.